Speeches and presentations
Search through our archive of speeches and presentations from conferences and events.
Visit our corporate reporting archive for our Annual Reports.
For quarterly results materials visit quarterly results.
09 July 2020
Investor and analyst call to discuss HIV Prevention Treatment Network 083 study
GSK held an investor/analyst call hosted by David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO, ViiV Healthcare and Dr. Kimberly Smith, Head of R&D, ViiV Healthcare to discuss the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN) 083 study evaluating investigational long-acting cabotegravir for HIV prevention.
This event took place on: Thursday 9 July at 14:00 BST / 09:00 EDT
13 February 2020
Guggenheim Healthcare Talks Idea Forum, New York City
Axel Hoos, Senior Vice-President Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum, Oncology Day, held in New York City on Thursday, February 13th, during which he provided an update on GSK Oncology R&D progress.
14 January 2020
38th annual JP Morgan Healthcare Conference, San Francisco
Emma Walmsley, CEO, presented at the 38th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 14 January, and provided an overview of GSK’s priorities and the progress the company made during 2019. The presentation was followed by a Q&A session.
17 December 2019
Investor and Analyst call from DREAMM-2 data
On Tuesday, 17 December 2019 at 17:00 GMT / 12:00 EST, Hal Barron, Chief Scientific Officer and President of R&D, Luke Miels, President Pharmaceuticals and Axel Hoos, SVP Oncology R&D hosted an investor/analyst conference call to discuss GSK’s pivotal DREAMM-2 data on belantamab mafodotin (GSK’916).
30 September 2019
Investor and Analyst call from ESMO 2019
On Monday, 30 September 2019, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of the PRIMA data on Zejula (niraparib) and the INDUCE-1 data on GSK’609 (ICOS) at the 2019 European Society for Medical Oncology (ESMO) congress. The call also featured participation from an external expert in ovarian cancer and other GSK senior oncology leaders.
26 September 2019
GSK Vaccines Investor Event
Roger Connor, President, GSK Vaccines, hosted an educational session on GSK’s Vaccines business at our manufacturing site in Wavre, Belgium on Thursday 26 September at 13:30 CET / 12:30 BST / 7:30 EDT.
12 June 2019
Goldman Sachs’ 40th Annual Global Healthcare Conference, California
Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at Goldman Sachs’ 40th Annual Global Healthcare Conference, which took place in Rancho Palos Verdes, California on Wednesday 12 June, during which he has provided an update on the progress being made in GSK’s R&D organisation.
06 June 2019
Jefferies 2019 Healthcare Conference, New York
David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, and Deborah Waterhouse, CEO of ViiV Healthcare, hosted a fireside chat at the Jefferies 2019 Healthcare Conference in New York on Thursday 6 June, during which they provided an update on the progress GSK and ViiV Healthcare have made this year.
04 June 2019
Bernstein Consumer Healthcare & Nutrition Seminar, London
Tobias Hestler, CFO GSK Consumer Healthcare, hosted a fireside chat at the Bernstein Consumer Healthcare & Nutrition Seminar in London on Tuesday 4 June during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.
30 April 2019
ViiV Healthcare analyst call
David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.
